Advertisement
Advertisement
KRRO
Korro Bio, Inc. Common Stock
13.25
USDSponsored
+1.13
+9.32%
Aug 07, 15:58 UTC -4
Closed
After-Market
13.30
+0.05
+0.36%
KRRO Earnings Reports
Positive Surprise Ratio
KRRO beat 15 of 27 last estimates.
56%
Next Report
Date of Next Report
Aug 18, 2026
Estimate for Q2 26 (Revenue/ EPS)
$218.57K
/-$1.47
Implied change from Q1 26 (Revenue/ EPS)
--
/-13.02%
Implied change from Q2 25 (Revenue/ EPS)
-85.03%
/-46.35%
Korro Bio, Inc. Common Stock earnings per share and revenue
On May 07, 2026, KRRO reported earnings of -1.69 USD per share (EPS) for Q1 26, beating the estimate of -1.87 USD, resulting in a 10.05% surprise. Revenue reached --, compared to an expected 625.67 thousand, with a -100.00% difference. The market reacted with a -3.37% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -1.47 USD, with revenue projected to reach 218.57 thousand USD, implying an decrease of -13.02% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
electroCore, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.33
Surprise
+23.40%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
FAQ
What were Korro Bio, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Korro Bio, Inc. Common Stock reported EPS of -$1.69, beating estimates by 10.05%, and revenue of $0.00, -100% below expectations.
How did the market react to Korro Bio, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -3.37%, changed from $13.34 before the earnings release to $12.89 the day after.
When is Korro Bio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 18, 2026.
What are the forecasts for Korro Bio, Inc. Common Stock's next earnings report?
Based on 9
analysts, Korro Bio, Inc. Common Stock is expected to report EPS of -$1.47 and revenue of $218.57K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement